Former premier Lin Chuan (林全) yesterday clarified that he would not be working to help promote government policies in his new role as chairman of TTY Biopharm Co (台灣東洋藥品).
He said that his efforts would be focused on elevating TTY Biopharm’s profile in international markets, and that success of the nation’s biotechnology sector is not dependent on any single company.
Market observers have been upbeat on Lin’s appointment to the helm of the pharmaceutical company, on expectations that he would work as a proponent of President Tsai Ing-wen’s (蔡英文) “five plus two” innovative industries plan, which includes the biotechnology sector.
As the Executive Yuan is not a regulator of industries, his appointment does not violate conflict of interest rules nor the revolving-door policy for government workers, Lin said at a news conference in Taipei.
“Not every former government worker aims to become a ‘guardian deity’ for businesses as they transition to the private sector,” Lin said.
Amid rapid consolidation among the world’s biggest pharmaceutical companies, Taiwanese biotechnology firms must be able to differentiate and distinguish themselves by specializing in a few chosen fields, he said.
Lin said that he and TTY Biopharm president Clark Hsiao (蕭英鈞) have set their sights on growing the firm’s revenue 10-fold to US$1 billion.
The company reported that sales last year rose 8.8 percent annually to NT$4.09 billion (US$138.39 million), driven by rising shipments of chemotherapy drugs from its contract manufacturing business.
Net income last year rose 7.5 percent annually to NT$1.35 billion, with earnings per share of NT$5.43, setting a new record high, the company said.
TTY Biopharm shares yesterday surged 8 percent to NT$109 before settling at NT$105.50, a 5 percent increase.
Lin’s appointment also spurred on rallies for several other biotechnology stocks during yesterday’s session, dealers said.
TARIFFS: The global ‘panic atmosphere remains strong,’ and foreign investors have continued to sell their holdings since the start of the year, the Ministry of Finance said The government yesterday authorized the activation of its NT$500 billion (US$15.15 billion) National Stabilization Fund (NSF) to prop up the local stock market after two days of sharp falls in reaction to US President Donald Trump’s new import tariffs. The Ministry of Finance said in a statement after the market close that the steering committee of the fund had been given the go-ahead to intervene in the market to bolster Taiwanese shares in a time of crisis. The fund has been authorized to use its assets “to carry out market stabilization tasks as appropriate to maintain the stability of Taiwan’s
STEEP DECLINE: Yesterday’s drop was the third-steepest in its history, the steepest being Monday’s drop in the wake of the tariff announcement on Wednesday last week Taiwanese stocks continued their heavy sell-off yesterday, as concerns over US tariffs and unwinding of leveraged bets weighed on the market. The benchmark TAIEX plunged 1,068.19 points, or 5.79 percent, to 17,391.76, notching the biggest drop among Asian peers as it hit a 15-month low. The decline came even after the government on late Tuesday authorized the NT$500 billion (US$15.2 billion) National Stabilization Fund (國安基金) to step in to buoy the market amid investors’ worries over tariffs imposed by US President Donald Trump. Yesterday’s decline was the third-steepest in its history, trailing only the declines of 2,065.87 points on Monday and
TARIFF CONCERNS: The chipmaker cited global uncertainty from US tariffs and a weakening economic outlook, but said its Singapore expansion remains on track Vanguard International Semiconductor Corp (世界先進), a foundry service provider specializing in producing power management and display driver chips, yesterday withdrew its full-year revenue projection of moderate growth for this year, as escalating US tariff tensions raised uncertainty and concern about a potential economic recession. The Hsinchu-based chipmaker in February said revenues this year would grow mildly from last year based on improving supply chain inventory levels and market demand. At the time, it also anticipated gradual quarter revenue growth. However, the US’ sweeping tariff policy has upended the industry’s supply chains and weakened economic prospects for the world economy, it said. “Now
An employment discrimination lawsuit against contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) might soon be expanded after a hearing in a federal court in San Jose, California, on Tuesday to add 15 plaintiffs to the case. According to a court document, the lawsuit, which was refiled in November last year as a form of a class action with 13 plaintiffs in California, wants to add 15 plaintiffs from Arizona, where TSMC is building up its wafer fab capacity. TSMC first committed between 2020 and last year to invest US$65 billion in three advanced wafer fabs in Arizona. It then pledged an
RSS